Ultimovacs (ULTI) småprat 1

HO5 · oktober 12, 2021, 8:44pm

Er det ikke frameshift-mutasjoner og Hubro han tenker på da? Var min første tanke ihvertfall.
De har uttalt mål om profylaktisk vaksine til de med lynch syndrom. Veldig liten del av befolkningen (0,1%), men de som har syndromet har 80 % sannsynlighet for å utvikle kreft.

polygon · oktober 12, 2021, 8:50pm

Både spørsmålet (som var mitt) og svarene, går på UV1. Hubro, frameshift-mutasjoner og lynch syndrom er nok ikke det de heller hadde i tankene.

Men det er veldig vanlig å tenke først på det selskapet man er investert i

HO5 · oktober 12, 2021, 9:09pm

Du har sikkert rett, men jeg fikk inntrykk av at de beveget seg ut i mer generelt terreng, og ikke spesifikt UV1. Hør 23.50.
For meg virker det som de snakker bredere. Uansett spennende om de tenker i slike baner for Ultimo også.

Fornybar · oktober 12, 2021, 9:15pm

Det har de gjort i flere år i Ultimovacs

TekBot · oktober 13, 2021, 6:02am

Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma

80% overall survival rate at 24 months follow-up

Oslo, 13 October 2021: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical
…
Vis børsmeldingen

stage leader in immune stimulatory vaccines for cancer, announced continuing
positive topline results in its ongoing U.S.-based Phase I clinical trial
evaluating the Company’s universal cancer vaccine, UV1, in combination with the
checkpoint inhibitor pembrolizumab as a first-line treatment in metastatic
malignant melanoma. The trial had previously reached its primary endpoint of
safety and tolerability and at 24 months of follow-up continues to demonstrate
strong signs of clinical response.

In the Phase I trial, patients were treated initially for 14 weeks with UV1 in
combination with pembrolizumab. At the cut-off date of October 12, 2021, every
patient in the first cohort had been followed for at least 24-months from the
start of their treatment. The overall survival rate after two years of follow-up
was 80% in this first cohort of 20 patients. As previously announced, median
progression free survival for these patients was 18.9 months.

The 24-month follow-up data compares favorably with an earlier large-scale study
of pembrolizumab alone, which showed an overall survival rate of 58% after 24
months and median progression-free survival of 5.5-11.6 months*.

“The combination of UV1 and pembrolizumab has a strong safety profile and
provides a prolonged and effective clinical response in advanced melanoma,” said
Jens Bjørheim, Chief Medical Officer of Ultimovacs. “These two-year follow-up
data suggest that the way in which UV1 mobilizes the immune system provides
patients with lasting benefits.”

“We believe that UV1 will play a transformative role in the treatment of solid
tumors, elevating patients’ response rates in combination with checkpoint
inhibitors and providing long-term clinical benefits.” said Carlos de Sousa, CEO
of Ultimovacs. “We look forward to sharing more detailed results of this ongoing
study at a major clinical oncology meeting in 2022.”

The 12-month follow-up data from Ultimovacs’ Phase I trial can be accessed here
(https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3823802&la
ng=en-GB&companycode=no-ulti&v=). For further information please also see the Q2
2021 financial report (http://asia.blob.euroland.com/press-releases-
attachments/1330542/ultimovacs-asa-q221-report.pdf).
Keytruda package inserts and Robert C, Ribas A, Schachter J, et al.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-
year results from an open-label, multicentre, randomised, controlled, phase 3
study. Lancet Oncol. 2019;20(9):1239-1251. doi:10.1016/S1470-2045(19)30388-2
                              ==ENDS==
About Ultimovacs
Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of
cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human
telomerase (hTERT), present in over 80% of cancers in all stages
of tumor growth. By directing the immune system to hTERT antigens, UV1 drives
CD4 helper T cells to the tumor to activate an immune system cascade and
increase anti-tumor responses. With a broad Phase II program, Ultimovacs aims to
clinically demonstrate UV1’s impact in multiple cancer types in combination with
other immunotherapies. Ultimovacs’ second technology approach, based on the
proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific
peptides and adjuvant in the same molecule and entered Phase I studies in 2021.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com (mailto:carlos.desousa@ultimovacs.com)
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com (mailto:hans.eid@ultimovacs.com)
Phone: +47 482 48632

Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com (mailto:mchang@lifesciadvisors.com)
Phone: +44 7483 284 853

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Joachim Midttun, Finance
Manager at Ultimovacs ASA, on 13 October, 2021 at 08:00 CET.

Kilde

enurs · oktober 13, 2021, 6:12am

Var ikke dette ekstreme tall? 80% vs 58%.
Snakker vi Fast track her eller?

AndyO · oktober 13, 2021, 6:14am

Tror du må utvide ambisjonene et lite hakk👊.

theroger · oktober 13, 2021, 7:27pm

bilde

polygon · oktober 13, 2021, 6:42am

Bare OS altså, men hvilken OS!

Null døde de siste seks månedene!

NÅ kan vi begynne å spekulere i om det har vært ytterligere en CR!

h3nk1 · oktober 13, 2021, 6:49am

What will Sweden do?

Fartin · oktober 13, 2021, 6:53am

Er det andre komonasjonsbehandlinger der ute under utvikling som vi kan måle mot?

hybrid · oktober 13, 2021, 6:54am

Animated GIF - Find & Share on GIPHY

theroger · oktober 13, 2021, 7:14am

FOCUS studien ute på Clinical Trials

alfred_e_neuman · oktober 13, 2021, 7:15am

ulti-erection

h3nk1 · oktober 13, 2021, 9:01am

Skal bli interessant å se hvordan analytikerne håndterer reprisingen og dataene. Hansken er kastet, hvem blir førstemann ut med analyser som argumenterer for (fortjent) premium prising?

Edit:

Timm · oktober 13, 2021, 9:44am

DnB har hevet til 200.

Markusf · oktober 13, 2021, 9:45am

Kilde til analyse?

Timm · oktober 13, 2021, 9:50am

Det er DnB Markets v Patrik Ling.

busk1 · oktober 13, 2021, 10:00am

Hva hever de kursmålet på da hvis de ikke ser høyere LOA enn før?

Timm · oktober 13, 2021, 10:03am

En grunn er ihvertfall at de hever prisen på UV1.